Sectors
IVA
Inventiva S.A.
4.74
5 x 4.80
1 x 4.82
bid
ask
-
0.01
0.21%
09:36 AM
timesize
| Ytd | 1.94% | |
| 1y | 32.40% |
4.74
day range
4.84
3.35
52 week range
7.98
| Open | 4.82 | Prev Close | 4.75 | Low | 4.74 | High | 4.84 | Mkt Cap | 246.40M |
| Vol | 13.83K | Avg Vol | 992.21K | EPS | -2.96 | P/E | -1.60 | Forward P/E | -5.16 |
| Beta | 0.70 | Short Ratio | 1.73 | Inst. Own | 25.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-30 | 50-d Avg | 4.19 | 200-d Avg | 5.05 | 1yr Est | 15.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-09-25 | 2026-06 | -0.42 | N/A | N/A | N/A |
| 2026-03-30 | 2025-12 | -0.23 | -1.07 | -0.84 | -365.22% |
| 2025-09-25 | 2025-06 | -0.41 | -1.89 | -1.48 | -361.73% |
| 2025-03-26 | 2024-12 | -0.44 | -2.19 | -1.75 | -398.10% |
| 2024-09-25 | 2024-06 | -0.56 | -1.01 | -0.45 | -81.10% |
| 2024-03-27 | 2023-12 | -0.4 | -1.25 | -0.85 | -211.66% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-19 | Truist Securities | Upgrade | Buy | |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-12 | Leerink Partners | Upgrade | Outperform | |
| 2025-11-18 | Guggenheim | Upgrade | Buy | Buy |
| 2025-11-06 | Wolfe Research | Upgrade | Outperform | |
| 2025-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Samsara BioCapital, LLC | 5.19M | 23.53M | 2.49% |
| 2026-03-30 | Caligan Partners, LP | 4.97M | 22.54M | 2.38% |
| 2026-03-30 | Paradigm Biocapital Advisors LP | 4.00M | 18.12M | 1.91% |
| 2026-03-30 | Millennium Management Llc | 2.99M | 13.53M | 1.43% |
| 2026-03-30 | Trails Edge Capital Partners, LP | 2.66M | 12.04M | 1.27% |
| 2026-03-30 | Franklin Resources, Inc. | 2.46M | 11.15M | 1.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 969.59K | 4.39M | 0.46% |
| 2026-05-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 685.40K | 3.10M | 0.33% |
| 2026-05-30 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 246.37K | 1.12M | 0.12% |
| 2026-03-30 | Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 227.92K | 1.03M | 0.11% |
| 2026-03-30 | Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 195.75K | 886.72K | 0.09% |
| 2026-04-29 | RUSSELL INVESTMENT CO-Tax-Managed U.S. Mid & Small Cap Fund | 67.80K | 307.14K | 0.03% |